Headlands Technologies LLC Has $2.18 Million Stock Position in ImmunityBio, Inc. $IBRX

Headlands Technologies LLC reduced its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 37.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 248,550 shares of the company’s stock after selling 148,620 shares during the quarter. Headlands Technologies LLC’s holdings in ImmunityBio were worth $2,176,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of IBRX. Hussman Strategic Advisors Inc. acquired a new position in shares of ImmunityBio during the 2nd quarter worth about $1,287,000. SEB Asset Management AB acquired a new stake in ImmunityBio in the 1st quarter valued at approximately $18,770,000. Winning Points Advisors LLC bought a new position in ImmunityBio in the 4th quarter worth approximately $1,430,000. BlackRock Inc. grew its stake in shares of ImmunityBio by 29.4% in the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after acquiring an additional 7,736,819 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in ImmunityBio by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after acquiring an additional 5,122,052 shares during the period. Institutional investors own 8.58% of the company’s stock.

Insider Buying and Selling at ImmunityBio

In other news, Director Christobel Selecky sold 159,478 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $9.02, for a total value of $1,438,491.56. Following the sale, the director directly owned 35,064 shares in the company, valued at approximately $316,277.28. This represents a 81.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the completion of the sale, the director owned 2,802,788 shares in the company, valued at $22,085,969.44. This trade represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 435,443 shares of company stock valued at $3,918,819. 66.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on IBRX. D. Boral Capital reiterated a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a research note on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. BTIG Research restated a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of ImmunityBio in a research report on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $8.05 on Monday. The firm has a market capitalization of $8.53 billion, a PE ratio of -8.30 and a beta of 0.03. The company’s fifty day moving average price is $7.88 and its two-hundred day moving average price is $7.83. ImmunityBio, Inc. has a 52-week low of $1.95 and a 52-week high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. Analysts predict that ImmunityBio, Inc. will post -0.44 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.